Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Forbion Capital Partners
Biotech
Backed by top VCs, biotech bags Alzheimer’s med in $2.2B deal
QuantumCell has committed $2.2 billion in milestones for a potentially symptom-relieving Alzheimer’s drug candidate that is on the cusp of phase 2.
Nick Paul Taylor
Jul 1, 2026 4:40am
CellCentric raises $220M to advance myeloma drug
May 6, 2026 7:00am
Sanofi backs Altesa's $75M series B to bankroll rhinovirus study
Feb 19, 2026 7:00am
European VCs join forces to boost regional biotech investment
Feb 12, 2026 5:00am
Protego tucks $130M series B into its fold
Dec 1, 2025 6:00am
Sparrow flits forward with $95M for midstage diabetes asset
Sep 24, 2025 11:22am
